Norgine BV - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Norgine BV (Norgine) is a pharmaceutical company that develops pharmaceutical products for diseases with unmet medical needs. The company develops drugs in the therapeutic areas of gastroenterology, incontinence, hepatology and critical and supportive care and pain management, among others. It offers the treatment of diseases related to gastrointestinal tract, gastric and hepatic conditions, critical and supportive care. Norgine offers drugs in the form of capsules, solutions, tablets, oral powder and medical device. The company also provides clinical supply services to organizations conducting clinical trials. Its business development activities include novel partnering, in-licensing, and out-licensing and alliance management. It operates in the UK, France, Belgium, Germany and the Netherlands, among others. Norgine is headquartered in Amsterdam, the Netherlands.

Norgine BV - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Norgine BV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Norgine BV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Norgine BV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Norgine BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Norgine BV, Medical Devices Deals, 2011 to YTD 2017 12
Norgine BV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Norgine BV, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 15
Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 16
Merus Labs Acquires Rights to Salagen and Estraderm MX from Novartis Pharma for USD30 Million 17
Merus Labs Acquires Sintrom from Novartis 18
Merus Labs Completes Acquisition Of Prescription Medicine Product From Novartis 19
Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 20
Merus Labs Acquires Canadian Rights Of Vancocin From Iroko International 21
Partnerships 22
Altacor Enters Into Co-Promotion Agreement With Norgine For Clinitas Dry Eye Product 22
Norgine Forms Joint Venture With SpePharm Holding 23
Norgine Expands Distribution Agreement With PharmaSwiss For Movicol 24
Norgine Enters Into Drug Discovery Agreement With Jubilant 25
Licensing Agreements 26
Access Pharma Enters into Licensing Agreement with Norgine for MuGard 26
Valeant Pharma Enters into Licensing Agreement with Norgine 27
Navidea Enters into License Agreement with Norgine for Lymphoseek 28
PlasmaTech Biopharma Expands Licensing Agreement with Norgine for MuGard 29
Norgine Enters Into Licensing Agreement With Innovacell For ICEF15 30
Norgine Enters Into Licensing Agreement With Pegasus Biosolutions 31
Norgine Expands Licensing Agreement With Medical Futures For NORMACOL 32
APR Applied Pharma Research And Labtec Enter Into Licensing Agreement With Norgine For Setofilm 33
Nycomed Enters Into Licensing Agreement With Norgine For MOVIPREP 34
Equity Offering 35
Merus Labs Raises USD21 Million in Private Placement of Shares upon Exercise of Warrants 35
Merus Labs Raises USD20 Million in Private Placement of Subscription Receipts 37
Merus Labs Completes Partial Exercise of Underwriter's Over Allotment Option for Public Offering of Shares for USD63 Million 38
Merus Labs Raises USD9.2 Million in Private Placement of Preferred Shares 39
Merus Labs Raises USD28.7 Million in Public Offering of Shares 40
Merus Labs International Completes Underwriters Exercise Of Full Over-Allotment Option Of Private Placement Of Shares For US$20.7 Million 41
Merus Labs Completes Private Placement Of Shares For US$4.4 Million 42
Merus Labs Announces Public Offering Of Common Shares For US$10.1 Million 43
Merus Labs Completes Private Placement Of US$0.53 Million 44
Merus Labs International Completes Private Placement For US$2.13 Million 45
Asset Transactions 46
Norgine Divests its MENA Operations and Product Rights to Acino 46
Aspen Pharmacare Acquires Southern African Operations and Product Rights from Norgine 47
Norgine to Sell UK Rights for Somnite and Camcolit 48
Okana Ventures Acquires North American Product Rights For Factive From Merus Labs For Up to US$3.4 Million 49
Acquisition 51
Norgine Acquires Merus Labs International 51
Norgine BV - Key Competitors 53
Norgine BV - Key Employees 54
Norgine BV - Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Joint Venture 56
Recent Developments 58
Product News 58
Jul 15, 2016: Norgine’s Partner Takeda Russia-CIS Launches MOVIPREP In Russia 58
May 24, 2016: New Positive Phase III Study For NER1006 – The First 1 Litre PEG-Based Bowel Preparation 59
Other Significant Developments 60
Feb 16, 2017: Norgine Rejoins The UK Pharmaceutical Trade Body ABPI 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61
List of Tables
Norgine BV, Pharmaceuticals & Healthcare, Key Facts 2
Norgine BV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Norgine BV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Norgine BV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Norgine BV, Deals By Therapy Area, 2011 to YTD 2017 10
Norgine BV, Medical Devices Deals, 2011 to YTD 2017 12
Norgine BV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 15
Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 16
Merus Labs Acquires Rights to Salagen and Estraderm MX from Novartis Pharma for USD30 Million 17
Merus Labs Acquires Sintrom from Novartis 18
Merus Labs Completes Acquisition Of Prescription Medicine Product From Novartis 19
Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 20
Merus Labs Acquires Canadian Rights Of Vancocin From Iroko International 21
Altacor Enters Into Co-Promotion Agreement With Norgine For Clinitas Dry Eye Product 22
Norgine Forms Joint Venture With SpePharm Holding 23
Norgine Expands Distribution Agreement With PharmaSwiss For Movicol 24
Norgine Enters Into Drug Discovery Agreement With Jubilant 25
Access Pharma Enters into Licensing Agreement with Norgine for MuGard 26
Valeant Pharma Enters into Licensing Agreement with Norgine 27
Navidea Enters into License Agreement with Norgine for Lymphoseek 28
PlasmaTech Biopharma Expands Licensing Agreement with Norgine for MuGard 29
Norgine Enters Into Licensing Agreement With Innovacell For ICEF15 30
Norgine Enters Into Licensing Agreement With Pegasus Biosolutions 31
Norgine Expands Licensing Agreement With Medical Futures For NORMACOL 32
APR Applied Pharma Research And Labtec Enter Into Licensing Agreement With Norgine For Setofilm 33
Nycomed Enters Into Licensing Agreement With Norgine For MOVIPREP 34
Merus Labs Raises USD21 Million in Private Placement of Shares upon Exercise of Warrants 35
Merus Labs Raises USD20 Million in Private Placement of Subscription Receipts 37
Merus Labs Completes Partial Exercise of Underwriter's Over Allotment Option for Public Offering of Shares for USD63 Million 38
Merus Labs Raises USD9.2 Million in Private Placement of Preferred Shares 39
Merus Labs Raises USD28.7 Million in Public Offering of Shares 40
Merus Labs International Completes Underwriters Exercise Of Full Over-Allotment Option Of Private Placement Of Shares For US$20.7 Million 41
Merus Labs Completes Private Placement Of Shares For US$4.4 Million 42
Merus Labs Announces Public Offering Of Common Shares For US$10.1 Million 43
Merus Labs Completes Private Placement Of US$0.53 Million 44
Merus Labs International Completes Private Placement For US$2.13 Million 45
Norgine Divests its MENA Operations and Product Rights to Acino 46
Aspen Pharmacare Acquires Southern African Operations and Product Rights from Norgine 47
Norgine to Sell UK Rights for Somnite and Camcolit 48
Okana Ventures Acquires North American Product Rights For Factive From Merus Labs For Up to US$3.4 Million 49
Norgine Acquires Merus Labs International 51
Norgine BV, Key Competitors 53
Norgine BV, Key Employees 54
Norgine BV, Other Locations 55
Norgine BV, Subsidiaries 55
Norgine BV, Joint Venture 56